| Drug General Information |
| Drug ID |
D06YEV
|
| Former ID |
DNC002580
|
| Drug Name |
Hydroxydimethylarsine Oxide
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C2H7AsO2
|
| Canonical SMILES |
C[As](=O)(C)O
|
| InChI |
1S/C2H7AsO2/c1-3(2,4)5/h1-2H3,(H,4,5)
|
| InChIKey |
OGGXGZAMXPVRFZ-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
9516, 405276, 550112, 583643, 585540, 609263, 820929, 820955, 825024, 825305, 825315, 825331, 826127, 828436, 830633, 830847, 830886, 831497, 833146, 854580, 855157, 3152853, 5070549, 6436179, 8018167, 8022881, 8023029, 8027709, 8027881, 8028368, 8150092, 8151668, 10317216, 10317237, 10534914, 11335883, 11361122, 11364913, 11367475, 11370037, 11374068, 11378207, 11404479, 11405987, 11447883, 11447931, 11449379, 11462094, 11484895, 11488986
|
| Target and Pathway |
| Target(s) |
Nitric-oxide synthase, endothelial |
Target Info |
Inhibitor |
[1]
|
|---|
| Aldose reductase |
Target Info |
Inhibitor |
[1]
|
|
BioCyc Pathway
|
Citrulline-nitric oxide cyclePWY-5453:Methylglyoxal degradation III
|
|
Acetone degradation I (to methylglyoxal)
|
|
KEGG Pathway
|
Arginine and proline metabolism
|
|
Metabolic pathways
|
|
Calcium signaling pathway
|
|
cGMP-PKG signaling pathway
|
|
HIF-1 signaling pathway
|
|
Sphingolipid signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
VEGF signaling pathway
|
|
Platelet activation
|
|
Estrogen signaling pathway
|
|
Oxytocin signaling pathwayhsa00040:Pentose and glucuronate interconversions
|
|
Fructose and mannose metabolism
|
|
Galactose metabolism
|
|
Glycerolipid metabolism
|
|
NetPath Pathway
|
Wnt Signaling PathwayNetPath_13:IL1 Signaling Pathway
|
|
TGF_beta_Receptor Signaling Pathway
|
|
PANTHER Pathway
|
Angiogenesis
|
|
Endothelin signaling pathway
|
|
Interleukin signaling pathway
|
|
PI3 kinase pathway
|
|
VEGF signaling pathway
|
|
Pathway Interaction Database
|
Plasma membrane estrogen receptor signaling
|
|
Validated transcriptional targets of AP1 family members Fra1 and Fra2
|
|
Angiopoietin receptor Tie2-mediated signaling
|
|
Thromboxane A2 receptor signaling
|
|
SHP2 signaling
|
|
VEGFR1 specific signals
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
PAR1-mediated thrombin signaling events
|
|
PathWhiz Pathway
|
Fructose and Mannose Degradation
|
|
Pyruvate Metabolism
|
|
Pterine Biosynthesis
|
|
Glycerolipid Metabolism
|
|
Galactose Metabolism
|
|
Reactome
|
ROS production in response to bacteria
|
|
Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
|
|
eNOS activation
|
|
Nitric oxide stimulates guanylate cyclase
|
|
VEGFR2 mediated vascular permeability
|
|
WikiPathways
|
ACE Inhibitor Pathway
|
|
EGF/EGFR Signaling Pathway
|
|
Myometrial Relaxation and Contraction Pathways
|
|
JAK/STAT
|
|
Corticotropin-releasing hormone
|
|
AGE/RAGE pathway
|
|
Endothelin Pathways
|
|
Leptin signaling pathway
|
|
Effects of Nitric Oxide
|
|
Metabolism of nitric oxide
|
|
AngiogenesisWP702:Metapathway biotransformation
|
|
Polyol Pathway
|
|
Metabolism of steroid hormones and vitamin D
|
| References |
| REF 1 | How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. |
|---|
